3 patients had relapsed disease, the remaining 35 were primary presentations and 17 patients were aged under 4 years, with 5 patients having Down Syndrome.
The patient cohort was obtained from the departmental database and clinical information and echo reports were obtained from hospital online record systems, PEPR and HeartSuite.Ĥ0 patients received a diagnosis of AML at BCH over the 5-year study period, 2 patients were excluded as they died prior to treatment, leaving 38 patients for analysis with a mean age of 6 years 10 months. Our aim was to assess the frequency of anthracycline-induced cardiotoxicity in the paediatric AML population, the effect of age, and the impact that dexrazoxane has had since its routine incorporation into anthracycline-containing treatment protocols. We conducted a retrospective analysis of all patients who had been diagnosed with AML at Birmingham Children’s Hospital (BCH), a large paediatric tertiary centre, over a 5-year period between January 2016 and January 2021. Subsequent analysis has resulted in its acceptance as a cardioprotective agent in the treatment of paediatric malignancies. Dexrazoxane has been shown as an efficacious agent in the prevention of anthracycline-induced cardiotoxicity, however, in 2011 its use in the paediatric population was contraindicated by the EMA due to lack of efficacy in this cohort and concerns about its side effect profile. Despite this, data regarding the frequency of cardiotoxicity amongst this population is rare in the United Kingdom and various risk factors have been associated, including age less than 4 years. ALL, AML, MDS & bone marrow failure BSH2021-PO-033 Anthracycline-induced cardiomyopathy in paediatric acute myeloid leukaemia-A single centre age-stratified retrospective analysis and the early impact of dexrazoxaneĬlaire Horgan 1,*, Yashashree Gupta 1, Jayashree Motwani 1ġHaematology, Birmingham Children’s Hospital, Birmingham, United KingdomĪbstract Content: As survival rates for paediatric acute myeloid leukaemia (AML) have improved over recent decades, the risk of anthracycline-induced cardiomyopathy has become an increasing concern for the treating clinician and can have detrimental effects on the quality of life of survivors.
0 kommentar(er)
